Your browser doesn't support javascript.
loading
Letter to Editor: Response to AASLD Editorial/Message from the President.
Koretz, Ronald L; Jakobsen, Janus C; Hauser, Goran; Nikolova, Dimitrinka; Gluud, Christian.
Afiliação
  • Koretz RL; Granada Hills, California.
  • Jakobsen JC; The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark.
  • Hauser G; The Department of Cardiology, Holbaek Hospital, Holbaek, Denmark.
  • Nikolova D; The Department of Gastroenterology, Clinical Hospital Centre Rijeka, Rijeka, Croatia.
  • Gluud C; The Cochrane Hepato-Biliary Group, Copenhagen Trial Unit, Centre for Clinical Intervention Research, Copenhagen, Denmark.
Hepatology ; 69(5): 2300, 2019 05.
Article em En | MEDLINE | ID: mdl-30276829
ABSTRACT
A commentary [1] criticized our systematic review regarding the use of direct-acting agents (DAAs) in chronic hepatitis C [2]. The following represents our major disagreements. Sustained virological response (SVR) is a non-validated surrogate outcome. The principles of evidence-based medicine require that it be validated in randomized clinical trials (RCTs) by showing parallel benefits in clinical outcomes [3]. This article is protected by copyright. All rights reserved.
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C Crônica Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Hepatology Ano de publicação: 2019 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Antivirais / Hepatite C Crônica Tipo de estudo: Clinical_trials Limite: Humans Idioma: En Revista: Hepatology Ano de publicação: 2019 Tipo de documento: Article